NK cells for the treatment of neuroblastoma

Phase II Pilot Study of Maximum Tolerated Dose of Activated Allogeneic Natural Killer (NK) Cells Infusion Incorporated to Standard Therapy to Treat Pediatric Patients with High Risk Neuroblastoma

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160918001

Enrollment

Registered

2016-09-18

Start date

2017-03-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High risk neuroblastoma Neuroblastoma NK cell

Interventions

NK cell dose is categorized into 3 tiers 1. One million cells/recipient&#039

s weight (kg) 2. Ten million cell/recipient&#039

s weight (kg) 3. Fifty million cell/recipient&#039

s weight (kg) NK cells will be harvested and prepared prior and during hematopoietic stem cell transplantation being done on the patient then activating NK cells will be administered into the patient,

Experimental Drug

NK cells

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age under 18 years 2. Diagnosed with high risk neuroblastoma 3. Treated at Ramathibodi Hospital 4. Shortening fraction 25% or more than 25% 5. Glomerular filtration rate 50 or more than 50 ml/1.73m2/min 6. Available stem cell transplantation in family members 7. No pregnancy 8. Signed informed consent

Exclusion criteria

Exclusion criteria: 1. Denied to enroll in the trial

Design outcomes

Primary

Measure	Time frame
quantity of NK cells 12 months cell/kg	—

Secondary

Measure	Time frame
Event free rate 1 year cases	—

Countries

Thailand

Contacts

Public ContactUsanarat Anurathapan

Faculty of Medicine Ramathibodi Hospital

Usanarat.anu@mahidol.ac.th66917745310

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026